These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 38822192)

  • 1. METTL3 facilitates prostate cancer progression via inducing HOXC6 m6A modification and stabilizing its expression through IGF2BP2-dependent mechanisms.
    He P; Liu X; Yu G; Wang Y; Wang S; Liu J; An Y
    Mol Cell Biochem; 2024 Jul; 479(7):1707-1720. PubMed ID: 38822192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer.
    Li J; Xie H; Ying Y; Chen H; Yan H; He L; Xu M; Xu X; Liang Z; Liu B; Wang X; Zheng X; Xie L
    Mol Cancer; 2020 Oct; 19(1):152. PubMed ID: 33121495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. METTL3-mediated m6A modification of pri-miR-148a-3p affects prostate cancer progression by regulating TXNIP.
    Li G; Liu J; Wang Y; Liu H; Fu J; Zhao Y; Huang Y
    Environ Toxicol; 2023 Oct; 38(10):2377-2390. PubMed ID: 37449729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. METTL3 promotes prostate cancer progression by regulating miR-182 maturation in m6A-dependent manner.
    Wang D; Wang X; Huang B; Zhao Y; Tu W; Jin X; Shao Y; Zhu Y; Lu G
    Andrologia; 2022 Aug; 54(7):1581-1591. PubMed ID: 35413135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. METTL3-mediated m6A modification of CDCA7 mRNA promotes COAD progression.
    Hua M; Zhai X; Chen Y; Yin D
    Pathol Res Pract; 2024 Aug; 260():155437. PubMed ID: 38959625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer-associated fibroblasts-derived exosomal METTL3 promotes the proliferation, invasion, stemness and glutaminolysis in non-small cell lung cancer cells by eliciting SLC7A5 m6A modification.
    Fan Y; Yu Y
    Hum Cell; 2024 Jul; 37(4):1120-1131. PubMed ID: 38625505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. METTL3/IGF2BP2 axis affects the progression of colorectal cancer by regulating m6A modification of STAG3.
    Yi J; Peng F; Zhao J; Gong X
    Sci Rep; 2023 Oct; 13(1):17292. PubMed ID: 37828232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. METTL3-mediated m
    Cheng X; Yang H; Chen Y; Zeng Z; Liu Y; Zhou X; Zhang C; Xie A; Wang G
    Cell Mol Biol Lett; 2024 Aug; 29(1):109. PubMed ID: 39143552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. m
    Lang C; Yin C; Lin K; Li Y; Yang Q; Wu Z; Du H; Ren D; Dai Y; Peng X
    Clin Transl Med; 2021 Jun; 11(6):e426. PubMed ID: 34185427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N
    Wang A; Zeng Y; Zhang W; Zhao J; Gao L; Li J; Zhu J; Liu Z; Huang JA
    Cell Mol Biol Lett; 2024 Aug; 29(1):106. PubMed ID: 39095708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. METTL3 facilitates tumor progression via an m
    Li T; Hu PS; Zuo Z; Lin JF; Li X; Wu QN; Chen ZH; Zeng ZL; Wang F; Zheng J; Chen D; Li B; Kang TB; Xie D; Lin D; Ju HQ; Xu RH
    Mol Cancer; 2019 Jun; 18(1):112. PubMed ID: 31230592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. m
    Shen C; Xuan B; Yan T; Ma Y; Xu P; Tian X; Zhang X; Cao Y; Ma D; Zhu X; Zhang Y; Fang JY; Chen H; Hong J
    Mol Cancer; 2020 Apr; 19(1):72. PubMed ID: 32245489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Silencing of METTL3 effectively hinders invasion and metastasis of prostate cancer cells.
    Chen Y; Pan C; Wang X; Xu D; Ma Y; Hu J; Chen P; Xiang Z; Rao Q; Han X
    Theranostics; 2021; 11(16):7640-7657. PubMed ID: 34335955
    [No Abstract]   [Full Text] [Related]  

  • 14. WTAP-mediated N6-methyladenine Modification of circEEF2 Promotes Lung Adenocarcinoma Tumorigenesis by Stabilizing CANT1 in an IGF2BP2-dependent Manner.
    Zheng H; Cao Z; Lv Y; Cai X
    Mol Biotechnol; 2024 Apr; ():. PubMed ID: 38619801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. METTL3 promotes the progression of osteosarcoma through the N6-methyladenosine modification of MCAM via IGF2BP1.
    Song D; Wang Q; Yan Z; Su M; Zhang H; Shi L; Fan Y; Zhang Q; Yang H; Zhang D; Liu Q
    Biol Direct; 2024 Jun; 19(1):44. PubMed ID: 38849910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The m6A Methyltransferase METTL3-Mediated N6-Methyladenosine Modification of DEK mRNA to Promote Gastric Cancer Cell Growth and Metastasis.
    Zhang HM; Qi FF; Wang J; Duan YY; Zhao LL; Wang YD; Zhang TC; Liao XH
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35742899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. m6A methyltransferase METTL3 promotes the progression of prostate cancer via m6A-modified LEF1.
    Ma XX; Cao ZG; Zhao SL
    Eur Rev Med Pharmacol Sci; 2020 Apr; 24(7):3565-3571. PubMed ID: 32329830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The "m6A writer" METTL3 and the "m6A reader" IGF2BP2 regulate cutaneous T-cell lymphomas progression via CDKN2A.
    Wang X; Hu M; Yu L; Wang X; Jiang X; Zhang G; Ding K
    Hematol Oncol; 2022 Oct; 40(4):567-576. PubMed ID: 35446451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methyltransferase-like 3 facilitates lung cancer progression by accelerating m6A methylation-mediated primary miR-663 processing and impeding SOCS6 expression.
    Li S; Lu X; Zheng D; Chen W; Li Y; Li F
    J Cancer Res Clin Oncol; 2022 Dec; 148(12):3485-3499. PubMed ID: 35907010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of the KDM5A/miRNA-495/YTHDF2/m6A-MOB3B axis facilitates prostate cancer progression.
    Du C; Lv C; Feng Y; Yu S
    J Exp Clin Cancer Res; 2020 Oct; 39(1):223. PubMed ID: 33087165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.